title: Investigation of release pattern of a drug with low solubility through asymmetric membrane capsules.
abstract: Asymmetric membrane capsules are a type of osmotic drug delivery systems. They are nondisintegrating capsules, which utilize osmotic pressure to drive the drug outwards for controlled delivery. Preceded by systems such as elementary osmotic pump, controlled porosity osmotic pump, single composition osmotic tablet this system has the advantage of simple and easy fabrication as it obviates the necessity of drilling an orifice into the drug delivery system. Moreover; it seems to be a low-cost alternative. The cellulose acetate capsule shell, on coming in contact with the aqueous medium shows in situ pore formation due to leaching of pore formers, which have been incorporated into the shell forming solution. Until date, a number of osmotic agents to the likes of sodium chloride, mannitol has been used to build up osmotic pressure inside the cell. The system is endowed with high water flux, which is a plus point for delivery of poorly soluble drugs like cephalexin in terms of increasing release rates. Studies envisaged in this research include the effect of different concentrations of different pore formers on in vitro drug release as well as the effect of modification of inner contents of the capsule. The system was successful in producing a gradual release of drug for 12 h.
authors.affiliation: Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, Pushp Vihar, Sector III, New Delhi-110 017, India.
authors.forename: P K
authors.initials: PK
authors.lastname: Sahoo
authors.forename: Harleen
authors.initials: H
authors.lastname: Makar
keywords: Asymmetric membrane capsules; cephalexin; glycerol; osmotically controlled; potassium hydrogen tartrate
references.citation: J Control Release. 2003 Apr 14;89(1):57-69
references.pmid: 12695063
references.citation: J Control Release. 1999 Aug 5;60(2-3):333-41
references.pmid: 10425338
references.citation: J Control Release. 1999 Mar 8;58(1):29-38
references.pmid: 10021487
references.citation: Am J Dis Child. 1992 Nov;146(11):1324-7
references.pmid: 1415072
references.citation: Expert Opin Pharmacother. 2006 Oct;7(15):2119-38
references.pmid: 17020437
references.citation: Pharm Res. 1991 Jan;8(1):88-92
references.pmid: 2014214
references.citation: Eur J Pharm Biopharm. 2008 Feb;68(2):289-97
references.pmid: 17616378
references.citation: J Control Release. 2000 Jul 3;67(2-3):309-22
references.pmid: 10825563
references.citation: Curr Med Res Opin. 2006 Oct;22(10):1879-92
references.pmid: 17022845
references.citation: Int J Pharm. 2004 Nov 22;286(1-2):81-8
references.pmid: 15501004
references.citation: J Control Release. 2003 Apr 14;89(1):5-18
references.pmid: 12695059
references.citation: PDA J Pharm Sci Technol. 2007 Jan-Feb;61(1):24-36
references.pmid: 17390701
references.citation: Drug Dev Ind Pharm. 2002 Sep;28(8):1015-21
references.pmid: 12378956
references.citation: Am Heart J. 1990 Aug;120(2):483-9
references.pmid: 2382633